I-Mab Biopharma (Hangzhou) Co., Ltd. INVESTMENT AGREEMENTInvestment Agreement • February 7th, 2024 • I-Mab • Pharmaceutical preparations • Macau
Hereinafter, the foregoing parties are collectively referred to as the “Parties”, and when a party is referred to as a “Party”, the other parties are referred to as the “Other Parties”.
Equity Transfer Agreement of I-Mab Biopharma Co., Ltd. February 6, 2024 Equity Transfer Agreement of I-Mab Biopharma Co., Ltd.Equity Transfer Agreement • February 7th, 2024 • I-Mab • Pharmaceutical preparations
This Equity Transfer Agreement of I-Mab Biopharma Co., Ltd. (this “Agreement”) is entered into on February 6, 2024 (the “Execution Date”) in the People’s Republic of China (the “PRC”) by and among:
Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd. February 6, 2024Equity Transfer Agreement • February 7th, 2024 • I-Mab • Pharmaceutical preparations
This Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd. (this “Agreement”) is entered into on February 6, 2024 (the “Execution Date”) in the People’s Republic of China (the “PRC”) by and among:
I-Mab Biopharma (Hangzhou) Co., Ltd. SHAREHOLDERS’ AGREEMENT February 6, 2024 SHAREHOLDERS’ AGREEMENTShareholders’ Agreement • February 7th, 2024 • I-Mab • Pharmaceutical preparations
The foregoing parties are referred to collectively herein as the “Parties”, and when a party is referred to as a “Party”, the other parties are referred to as the “Other Parties”.
I-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaI-Mab • February 7th, 2024 • Pharmaceutical preparations
· Agreement provides for a strategic focus in advancing I-Mab’s potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing operational costs, and mitigating potential associated risks
